Allbiosyn Biotechnology completes Angel Round financing to advance small nucleic acid therapeutics

On September 24th, Allbiosyn Biotechnology Co., Ltd. ("Allbiosyn") announced the official completion of its Angel Round financing recently. This round of financing was jointly invested by Shenzhen Jinhang Qiying Venture Capital Fund (深圳金航启盈创业投资基金合伙企业), Zhuhai Jinhang Venture Capital Fund (珠海市金航创业投资基金合伙企业（有限合伙）), and Zhuhai Huazhong Chuanghang No. 2 (珠海市华众创航贰号企业管理咨询合伙企业(有限合伙)). 

The funds raised will be mainly used for the R&D and production of key raw materials for nucleic acid drugs, preclinical research and IND (Investigational New Drug) application of core pipeline drugs, iteration and upgrading of key technology platforms, expansion of the core R&D team, and construction of laboratory infrastructure. These investments will inject strong impetus into the company's technological breakthroughs and industrialization implementation in small nucleic acid drug development.

Since its establishment, Allbiosyn Biotechnology has adhered to the vision of "Safeguarding human health with innovative pharmaceutical technologies" and focused on technological breakthroughs and product innovation in the field of small nucleic acid drugs. The company's core team consists of senior scientists with over 20 years of experience in pharmaceutical R&D, medical experts with rich clinical experience, and industry veterans with management experience in multinational pharmaceutical companies. It has accumulated profound technological reserves and project experience in key technologies, including: new polyphosphorylation technology, new green nucleic acid synthesis technologies (enzymatic catalysis technology, crystallization and purification processes), RNA cyclization modification technology, nucleic acid drug building block technology, nucleic acid drug selective delivery technology, enzymatic catalysis Oligo synthesis technology, and small nucleic acid liquid-phase synthesis technology.

Currently, the company has established the "Polyphosphorylation Enzymatic Catalysis Technology Platform" and "Small Nucleic Acid Drug Delivery Technology Platform", and has launched multiple R&D projects focusing on the Anti-KRAS siRNA targeted drug pipeline for pancreatic cancer. The completion of this Angel Round financing will further accelerate the optimization of the company's technology platforms and the advancement of R&D projects, helping the company seize the technological high ground in the fierce industry competition.